Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.07.016
Abstract: Introduction: This study evaluated whether tumor expression of programmed death ligand 1 (PD‐L1) could predict the response of EGFR‐mutated NSCLC to EGFR tyrosine kinase inhibitor (TKI) therapy. Methods: We retrospectively evaluated patients who received EGFR‐TKIs… read more here.
Keywords: response; novo resistance; programmed death; resistance ... See more keywords
Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0130
Abstract: Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor microenvironment (TME), we used single-cell transcriptional profiling to map… read more here.
Keywords: novo resistance; myeloid cells; blockade; resistance ... See more keywords